Breo Ellipta Lawsuit 2026: The $89.7 Million Patent Case and Active Injury Claims
Quick Answer
- The main Breo Ellipta lawsuit was a patent case won by Vectura against GSK, resulting in an $89.7 million judgment in 2019 .
- That patent verdict was a business dispute between drug companies, not a consumer payout, so patients cannot claim from it.
- Separate patient injury lawsuits over pneumonia and cardiovascular side effects are still active, with no settlement fund or claim deadline announced .
The Breo Ellipta lawsuit is real, but it is not one case. There are two completely different legal fights happening under this name, and confusing them is easy.
The first is a patent infringement case between two pharmaceutical companies over inhaler technology. Vectura sued GSK and won $89.7 million in damages in 2019 . That money went to Vectura, not to patients.
The second involves individual patients who used Breo Ellipta and claim it caused serious harm, including pneumonia and heart problems. Those cases are still moving through courts with no settlement announced .
This guide explains both tracks, what the FDA label warns about, and what you should do if you believe Breo Ellipta harmed you. The most important verified fact: no consumer settlement exists yet, so anyone promising you a payout today is not telling the truth.
The Facts
| Patent Case | Vectura Ltd. v. GlaxoSmithKline |
| Verdict | $89.7 million |
| Status | Resolved (2019 verdict, affirmed 2020) |
| Patient Injury Cases | Active, no settlement |
| Fund Size | Not yet confirmed |
| Est. Per Person | Not yet determined |
| Claim Deadline | None announced |
| Proof Needed | Check court notices if class is certified |
Is the Breo Ellipta lawsuit a class action settlement?
No. The Breo Ellipta lawsuit is not a settlement you can claim from today. The main case was a patent dispute between two companies, and the patient injury claims are individual lawsuits .
The patent case ended with a jury verdict in May 2019. The jury found GSK willfully infringed Vectura’s patent covering dry-powder inhaler technology used in Breo Ellipta, Anoro Ellipta, and Incruse Ellipta . The Federal Circuit affirmed the verdict in November 2020 .
That $89.7 million went to Vectura, a British pharmaceutical technology company. It did not create a fund for patients.
Separately, some patients have filed individual lawsuits claiming Breo Ellipta caused serious side effects and that the warnings were inadequate. Those cases are not consolidated into a class action, and no settlement has been announced .
How much could Breo Ellipta injury settlement pay?
The Breo Ellipta injury settlement payout is not yet determined. No settlement has been reached, and no court has approved any payment amount for patients.
The patent verdict of $89.7 million is not a patient payout. That number represents a 3% royalty on $2.99 billion in sales of the infringing inhalers . It was calculated to compensate Vectura for GSK’s use of its patented technology.
If patient injury cases ever settle, payouts would depend on several factors: how many claimants file valid claims, what proof of injury is required, and how the settlement fund is structured. No cap or tier system has been announced.
Who may qualify for a Breo Ellipta injury claim?
You may qualify if you used Breo Ellipta and experienced serious side effects that you believe were caused by the medication. The FDA label lists pneumonia, cardiovascular problems, and adrenal insufficiency as known risks .
The label specifically warns that people with COPD have a higher chance of getting pneumonia while using Breo Ellipta . It also lists effects on the heart, including increased blood pressure, fast or irregular heartbeat, and chest pain .
Other serious risks include adrenal insufficiency, weakened immune system, bone thinning, eye problems like glaucoma and cataracts, and slowed growth in children .
There is no eligibility list or claims process right now. If a class action is ever certified or a settlement is reached, rules would be published in official court notices.
What was the Breo Ellipta patent lawsuit about?
The Breo Ellipta patent lawsuit was about inhaler technology, not patient safety. Vectura sued GSK in 2016, claiming the Ellipta inhaler range infringed its patent for composite active particles used in pulmonary delivery .
The patent covered the use of magnesium stearate as an additive to improve how medication disperses in the lungs. Vectura argued GSK incorporated this patented process without authorization .
A Delaware jury agreed. In May 2019, after a five-day trial, the jury found GSK willfully infringed Vectura’s patent and awarded $89.7 million in damages . The Federal Circuit affirmed the verdict in November 2020 .
GSK paid the judgment. The patent case is resolved and closed.
What are the patient injury claims about?
The patient injury claims allege that Breo Ellipta caused serious harm and that GSK failed to adequately warn about those risks. The most common allegations involve pneumonia and cardiovascular complications .
The FDA label does warn about these risks. It states that Breo Ellipta may increase the chance of getting pneumonia in COPD patients . It also lists cardiovascular effects including increased blood pressure and irregular heartbeat .
Patients who filed suit argue the warnings were insufficient or that the risks were downplayed. GSK denies the allegations and maintains that the label adequately discloses the known risks.
These cases are individual lawsuits, not a class action. They remain in various stages of litigation with no settlement announced .
Key Takeaway: The Breo Ellipta patent case paid $89.7 million to Vectura, not to patients, while patient injury claims remain active with no settlement fund or claim deadline.
Reality Check
If someone contacts you claiming you are owed money from a “Breo Ellipta settlement,” that is a scam. No settlement fund exists for patients, no administrator has been appointed, and no court has approved any payout. The $89.7 million patent verdict went to a pharmaceutical company, not to consumers. Never pay anyone to “process” a claim for a case that has not settled.
What does the FDA label warn about Breo Ellipta?
The FDA label for Breo Ellipta lists several serious side effects that patients should know about. These warnings are part of the official prescribing information .
The most important warning involves pneumonia. The label states that people with COPD have a higher chance of getting pneumonia, and Breo Ellipta may increase that risk . Symptoms include increased mucus production, fever, chills, and increased breathing problems.
Cardiovascular effects are also listed. These include increased blood pressure, fast or irregular heartbeat, and chest pain .
Other serious risks include:
- Adrenal insufficiency: A condition where adrenal glands do not make enough steroid hormones, which can worsen under stress and may cause death
- Weakened immune system: Increased chance of getting infections
- Bone thinning (osteoporosis)
- Eye problems: Including glaucoma and cataracts
- Slowed growth in children
The label recommends rinsing your mouth with water without swallowing after each use to help prevent thrush, a fungal infection in the mouth or throat .
What should you do if Breo Ellipta harmed you?
Take these steps to protect your rights if you believe Breo Ellipta caused you harm.
- Stop using the medication only after consulting your doctor, since stopping suddenly can worsen breathing problems .
- See your doctor and report all symptoms you believe are related to the medication.
- Request your medical records documenting your diagnosis and treatment.
- Save your prescription records showing when you used Breo Ellipta.
- Write down a timeline of when you started the medication and when symptoms appeared.
- Report side effects to the FDA through its MedWatch program.
- Consult a product liability attorney about your individual options.
What happens next in the Breo Ellipta injury cases?
The patient injury cases will continue through the courts. No dates are confirmed beyond what has already occurred.
2019-2020: Patent verdict and appeal resolved.
2021 onwards: Individual injury cases filed and proceeding.
TBD: Any consolidation, class certification, or settlement announcement.
TBD: If settled, a claims process and payment distribution.
There is no public timeline for resolution. Product liability cases can take years.
Frequently Asked Questions
Is the Breo Ellipta lawsuit a class action settlement?
No. The main case was a patent dispute between companies. Patient injury claims are individual lawsuits.
How much can I get from the Breo Ellipta lawsuit?
Nothing from the patent case. Patient injury payouts are not yet determined.
Who received the $89.7 million verdict?
Vectura Ltd., the patent holder. The money did not go to patients .
Does Breo Ellipta cause pneumonia?
The FDA label warns that Breo Ellipta may increase the chance of getting pneumonia in COPD patients .
Can I sue GSK over Breo Ellipta side effects?
Yes, potentially. You would need to prove the medication caused your injury and consult an attorney about your state’s deadline.
What is the deadline to file a Breo Ellipta claim?
No claim deadline exists because no settlement has been reached.
Is Breo Ellipta still on the market?
Yes. The patent case did not result in a recall or withdrawal .
What should I do if I have side effects from Breo Ellipta?
See your doctor, document your symptoms, and consult a product liability attorney about your options.
Your next step
If you used Breo Ellipta and experienced pneumonia, heart problems, or other serious side effects, document everything today. Save your prescription records, get your medical records, and write down your timeline.
There is no settlement to claim right now. The most important action is preserving evidence and consulting an attorney before any statute of limitations deadline passes.
